Inovio Pharmaceuticals, Inc. (0A43)
London Stock Exchange · UK · prices in USD · close of 27 Oct 2026
Key indicators
| Last close | USD 0.920 |
|---|---|
| 52-week range | 0.567 – 2.719 |
| Return, 1 month / 3 months | −22.1% / −5.4% |
| Return, 1 year / 3 years | −63.2% / −79.0% |
| Trend | Below its 200-day average |
| RSI (14) | 40 |
| Volatility (1 year) | 103.2% |
| Worst drawdown (1 year) | -75.6% |
| Average daily value traded | 0.07M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Inovio Pharmaceuticals is a biotechnology company that designs and develops DNA-based vaccines and immunotherapies. Its work centres on products intended to prevent or treat infectious diseases and cancers, using technology that delivers genetic instructions into cells so the body can mount an immune response. The company carries out research and clinical development and works with partners and public health bodies on vaccine programmes. It is based in the United States.
Inovio Pharmaceuticals, Inc. trades under the code 0A43 on the London Stock Exchange in UK, with its price quoted in US dollars (USD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Inovio Pharmaceuticals, Inc. (0A43) trades on the London Stock Exchange in UK. It last closed at USD 0.920 on 27 October 2026.
Its price-based Market X-Ray is 15 out of 100 (a weak price profile), ranking 3,571 of 3,788 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 63.2% and over the last three months it fell 5.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Stock Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 12 · Weak | Below its long-term averages and far from its highs. | |
| Above 200-day average | -28.1% | ||
| From 52-week high | -65.4% | ||
| Momentum | 20 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -5.4% | ||
| 6-month return | -20.7% | ||
| 12-month return, skipping the last month | -52.8% | ||
| Stability (higher is calmer) | 6 · Weak | Volatile, with deep drawdowns. | |
| Volatility, 1 year (lower is calmer) | 103.2% | ||
| Worst drawdown, 1 year (smaller is calmer) | -75.6% | ||
| Liquidity | 27 · Weak | Thinly traded: prices can jump and exits can be hard. | |
| Average daily value traded | 0.07M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
No lens stands out as a clear strength against its exchange.
Weak spots
- Trend: Below its long-term averages and far from its highs.
- Momentum: Lagging most stocks on this exchange.
- Stability (higher is calmer): Volatile, with deep drawdowns.
- Liquidity: Thinly traded: prices can jump and exits can be hard.
Returns
| 1 week | −9.8% |
|---|---|
| 1 month | −22.1% |
| 3 months | −5.4% |
| 6 months | −20.7% |
| 1 year | −63.2% |
| 3 years | −79.0% |
| 5 years | −98.9% |
Signals
| 50-day / 200-day average | 1.170 / 1.280 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.103 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Stock Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.